Evidence check: HbA1c in the context of longevity

HbA1c (glycated hemoglobin) is a well-validated marker of average blood glucose over 2–3 months. In longevity research, lower HbA1c within the normal range (<5.7%) is associated with reduced risk of age-related diseases such as cardiovascular disease, kidney dysfunction, and cognitive decline. Evidence comes mainly from large observational cohorts (e.g., NHANES, EPIC) and diabetes intervention trials. However, the ACCORD trial showed that overly aggressive glucose lowering in diabetics increased mortality, suggesting a U-shaped risk curve. For non-diabetic individuals, an HbA1c between 4.5% and 5.6% is likely optimal, but direct longevity outcome trials are lacking. The test is reliable but can be confounded by anemia, hemoglobin variants, or renal impairment. A single HbA1c value should not replace a comprehensive metabolic assessment. Evidence grade: human-moderate. Safety note: Do not pursue extreme dietary measures to lower HbA1c without medical supervision.